MONMOUTH JUNCTION, N.J. USA – March 3, 2010 — MicroDose Therapeutx Inc. today announced that it has been invited to give a corporate presentation at Cowen & Company, LLC’s 30th Annual Healthcare Conference being held at the Boston Marriot Copley Place, Boston, MA from Monday March 8th through Thursday, March 11th, 2010.

Anand V. Gumaste, PhD, MicroDose’s President and Chief Executive Officer, will provide an overview of the company on Tuesday, March 9th at 10:00a.m. Eastern Standard Time.

About MicroDose Therapeutx

MicroDose Therapeutx is a privately-held specialty pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral and transdermal delivery of medications. The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies. MicroDose’s products and platforms currently target respiratory disease states such as asthma, COPD and RSV disease, as well as constipation and diabetes among others.

For more information on MicroDose Therapeutx, please visit www.mdtx.com or contact:

Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

Acquisition expands MicroDose’s portfolio in its PolyCap® oral delivery platform

MONMOUTH JUNCTION, N.J. USA – December 1, 2009 — MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA). The lead compound in the portfolio, formerly known as EPX-16006, is a novel, highly selective, oral, small molecule, now called MDT-006. The compound is extremely potent, possibly allowing for once-a-day dosing, and has demonstrated efficacy and safety in preclinical studies. Because of MDT-006’s unique mechanism of action, it may also have application in non-gastrointestinal diseases. MicroDose intends to develop MDT-006 initially in an oral format using its PolyCap® delivery platform.

Commenting on the product acquisition, Mike Martin, Vice President, Licensing and Business Development at MicroDose said “Current pharmaceutical options are extremely limited to treat chronic constipation resulting from IBS and there is a substantial commercial opportunity for a safe and effective therapy. MDT-006 offers an attractive approach to current therapy and because the compound acts primarily on the colon and is not absorbed, it is expected to have fewer gastrointestinal and systemic side effects.”

MicroDose acquired EPIX’s global rights to the compounds in an outright purchase for cash. The acquisition includes rights to EPX 16006, its chemical analogues and supporting patents and development data, including toxicology studies and related materials. MicroDose plans to further develop MDT-006 internally and to seek partnering opportunities at an appropriate future stage of the development program.

The EPIX transaction is the second portfolio acquisition by MicroDose in the last two months. MicroDose earlier announced its purchase from ViroPharma Incorporated of anti-viral investigational compounds (MDT-637) for the potential prevention and treatment of respiratory syncytial virus or RSV disease.

About IBS disease

While the exact cause of Irritable Bowel Syndrome is unknown, it is estimated that between 20 and 40 million US adults suffer from this disease. While both genders are candidates for IBS there is a higher incidence among women. According to Datamonitor, “IBS is one of the most common functional disorders and is one of the top 10 reasons for visits to primary care physicians.” Symptoms of the disease include constipation, abdominal pain, bloating, and fatigue. IBS is often prevalent among patients suffering from psychiatric disorders such as depression and anxiety.

About MDT-006

MDT-006 is a novel, highly selective, non absorbed, small molecule. In pre-clinical animal studies, the compound increased feces production and water content, reduced gastrointestinal transit time and further had no detectable plasma levels. MDT-006 has many potential uses, including as a treatment for chronic constipation and constipation related to IBS (IBS-C) and to side effects associated with medications and surgical procedures. It may also have applications for respiratory and ocular indications.

About PolyCap®

MicroDose’s patented PolyCap® system is a proprietary approach that enables the rapid development of fixed-dose-combination therapies in a single capsule, but separated by a physical barrier. This innovative approach relies on the proven strengths of capsules and the advantages of a barrier system, allowing for more rapid product development timelines, reduced development risk, and lower regulatory requirements.

About MicroDose Therapeutx

MicroDose Therapeutx is a privately-held specialty pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral and transdermal delivery of medications. The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies. MicroDose’s products and platforms currently target respiratory disease states such as asthma, COPD and RSV disease, as well as diabetes, hypertension and hyperlipidemia. For more about MicroDose, see our website at www.mdtx.com.

Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

Judith Fleischer, Ex Machina D x M, 908-469-0554 or jfleischer@exmachinadxm.com

MicroDose Therapeutx Acquires ViroPharma Portfolio of Investigational Compounds for Treatment of Respiratory Syncytial Virus (RSV)

Acquisition expands MicroDose’s portfolio of proprietary products.

MONMOUTH JUNCTION, N.J. USA—November 9, 2009—MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA).  The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.  This highly potent compound has demonstrated antiviral activity in preclinical studies in both prophylaxis and treatment, and was generally well tolerated in multiple adult volunteer Phase I studies.  MicroDose plans to develop the newly acquired compound in dry powder format for inhalation via MicroDose’s novel dry powder inhaler (DPI).

RSV is a highly contagious virus that is a major health threat to several high-risk populations and, with no effective treatments presently available, represents a major unmet medical need. RSV infects over 90% of children worldwide during the first two years of life and causes considerable morbidity and mortality in premature infants, the immuno-compromised, the elderly, and individuals with asthma and chronic obstructive pulmonary disease (COPD).

Commenting on the acquisition, Anand Gumaste, President & CEO of MicroDose said, “Earlier this year we announced that we would be expanding our mission by developing proprietary products that address large market opportunities and are enabled by our game-changing drug delivery technologies.  The acquisition of ViroPharma’s portfolio is a perfect fit with this strategy, as it leverages our next generation inhaler platform as well as our experience in respiratory product development to address a large unmet need in RSV disease.”

“The unique capabilities of the MicroDose inhaler are ideal for the delivery of MDT-637 as it can realize the molecule’s broadest potential across the range of populations from pediatric to the elderly, groups not well served by today’s DPIs.  The potential for both treatment and prevention across this spectrum of patients, combined with non-invasive inhaled delivery to the site of infection, could greatly expand this market,” explains Scott Fleming, MicroDose’s Sr. Vice President, Sales & Marketing.

About RSV disease

RSV is a pathogen that attacks the human respiratory tract.  There are currently no treatment options approved in the U.S. for this virus among the infant, pediatric, and adult populations that are susceptible to it.  The February 2009 edition of the New England Journal of Medicine stated that “RSV is associated with substantial morbidity in US children in both the inpatient and outpatient settings and….. its control is a worldwide priority.”  Globally, the annual death rate from RSV is estimated at 160,000 and the clinical burden of RSV infection is comparable to that of influenza.  The market opportunity for treatments addressing RSV is significant and growing.  MedImmune’s monoclonal antibody, Synagis^®, an intramuscular injection approved only for prophylactic use against RSV in premature infants, has annual worldwide sales in excess of $1 billion.

About MDT-637

MDT-637 is a clinical stage product that has been shown to effectively block RSV infection both in vitro and in the cotton rat, which is the accepted animal model for RSV infection.  MDT-637 acts by targeting the viral fusion protein, which is the only validated target for RSV treatments. The compound is inhaled, which allows for rapid delivery to the site of virus infection, the lungs, and has been shown to be safe and well tolerated in multiple human safety trials.  Results from animal studies indicate that MDT-637 could find use as both a preventative and a treatment of RSV infection.  MDT-637 will be formulated for pulmonary delivery via MicroDose’s proprietary dry powder inhaler.

About MicroDose Therapeutx

MicroDose Therapeutx is a privately-held specialty pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases.  The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral, and transdermal delivery of medications.  The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies.  MicroDose’s products and platforms currently target respiratory disease states such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory syncytial virus (RSV), as well as diabetes, hypertension, and hyperlipidemia. More can be found at our website; www.mdtx.com.

Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

Judith Fleischer, Ex Machina D x M, 908-469-0554 or jfleischer@exmachinadxm.com

Monmouth Junction, NJ, USA—April 27, 2009— MicroDose Technologies, a leader in next generation drug delivery technologies, is now MicroDose Therapeutx (MDT). Founded in 1998 with the introduction of its revolutionary electronic dry powder inhaler among other technologies, privately held MicroDose Therapeutx focuses on the creation of products utilizing its proprietary drug delivery technologies.

The MDT name change reflects the expansion of its business, its capabilities and its products. The company plans to expand its portfolio from primarily third party products incorporating its technologies to one that includes internally developed specialty pharmaceutical products. Utilizing its game changing drug delivery technologies, MicroDose Therapeutx plans to create easy to use therapies with improved performance, safety and efficacy. In addition to its new name, MDT has launched a new web site, www.mdtx.com.

MDT’s focus in pulmonary delivery is on inhalation therapies for respiratory diseases like asthma and COPD, and supportive care for respiratory illnesses, such as pulmonary infections. Other priority areas include treatments for pain, diabetes and pulmonary hypertension, where pulmonary delivery can enhance efficacy. For oral dosage products utilizing our PolyCap® system, we will focus on products that enhance treatment effectiveness in patients suffering from major diseases like diabetes, hypertension, and hyperlipidemia.

Describing the new vision for the company, Anand Gumaste, President and Chief Executive Officer, states, “The name change reflects our decision to expand the company’s business model from a strictly technology out-licensing model to one where the company would also carry certain pharmaceutical products through proof-of-concept before out-licensing or seeking partners for further development. This expansion of our business strategy will give us a greater degree of control over the company’s growth.”

About MicroDose Therapeutx

MicroDose Therapeutx (MDT), formerly MicroDose Technologies, is dedicated to improving the quality of life for people suffering from serious diseases by creating improved pharmaceutical products. The company is a leader in the application of proprietary drug delivery technologies; developing advanced pulmonary, combination oral dosage; and other technologies and products for the pharmaceutical and biotechnology industries.

MicroDose’s partners and programs include: multi-product licensing and development agreements with Novartis and Merck & Co., Inc., the joint development of an inhaled insulin product, and an inhaler for the delivery of a nerve agent antidote for the US Department of Defense.

Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

As previously announced, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds. In addition to the upfront payment received upon commencement of the collaboration, MicroDose is eligible for additional milestone payments on this product and for the development of other products and royalties on revenues from all products developed under the license.

“MicroDose is proud to announce the start of the study by Merck which, in fact, represents the second human clinical study to be initiated under a U.S. Investigational New Drug application using our inhaler technology in the last 18 months” commented David Byron, Vice President of Research and Development, MicroDose. “Achieving this milestone with Merck so quickly is a strong indicator of the excellent working relationship that underpins this collaboration.”

About the MicroDose DPI The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture, features MicroDose hopes will be confirmed through clinical trials. MicroDose believes that the flexibility of the
inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries. In addition to the collaboration with Merck, MicroDose’s other partnerships include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the U.S. Department of Defense, in collaboration with the University of Pittsburgh.

MicroDose has ongoing feasibility programs with other major pharmaceutical companies and is also conducting internal development programs for products employing its inhaler technology, and for combination oral dosage products employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
SOURCE MicroDose Technologies, Inc

Under the terms of the agreement, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds. MicroDose will receive an upfront payment and will be eligible for milestone payments totaling $32 million for successful development of the first product as well as royalties on product revenues. Additional products will also be eligible for milestones and royalties.

“We are delighted to expand our relationship with Merck, who have already proved to be very collaborative and decisive in their actions,” commented Scott Fleming, Senior Vice President, Marketing of MicroDose. “This agreement to bring innovative inhalation products to market is a positive milestone in the continued growth of MicroDose and represents further validation of our DPI technology.”

“Through this agreement Merck has gained access to a novel delivery technology that has the potential to facilitate the
administration of and ensure patient compliance with drug treatments targeting the lungs,” said Soren Bo Christiansen, General Manager Bone, Respiratory, Immunology and Endocrine Franchise, Merck & Co., Inc. “This approach is consistent with our leadership strategy of developing respiratory medicines that address unmet medical needs and deliver value to patients, physicians and payers.”

About MicroDose DPI

The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance, versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture. MicroDose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries.

MicroDose’s partnered programs include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the University of Pittsburgh. MicroDose is also conducting internal development programs for products employing its inhaler technology and for combination oral dosage products, employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
Website: http://www.microdose-tech.com//

MicroDose’s partnered programs include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the University of Pittsburgh. MicroDose is also conducting internal development programs for products employing its inhaler technology and for combination oral dosage products, employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
Website: http://www.microdose-tech.com//

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2008 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company

As part of the revised agreement, Innovata, MicroDose and QDose will receive undisclosed payments from Bristol-Myers Squibb, which will share in certain future revenues generated by the QDose inhaled insulin product. In addition, all intellectual property rights, data, materials and know-how generated during the course of the collaboration will become the property of QDose.

Kieran Murphy, Chief Executive Officer of Innovata, said: “In the last two years, the inhaled insulin programme has made substantial progress. When it became clear that the project may not be in line with Bristol-Myers Squibb’s long-term strategic goals, it made sense for this current arrangement to be brought to a conclusion. We remain fully convinced of the product’s potential and are confident that it will attract significant interest from prospective partners with strategic interests in the treatment of diabetes. In the meantime, QDose will continue to build on the progress achieved to date by completing preparations for an IND submission to the US Food and Drug Administration.”

Contacts:
Innovata plc
Kieran Murphy, Chief Executive Officer
Tel: 0115 974 7474

Financial Dynamics
Sarah MacLeod / John Gilbert
Tel: 020 7831 3113

MicroDose Technologies, Inc.
Scott Fleming, Head of Marketing
Tel: +1 732 355 2100

About Innovata plc

Innovata plc specialises in the development of pulmonary products for the treatment of respiratory disorders and other serious diseases. Using its proprietary dry powder inhaler and drug formulation technologies, Innovata plc has developed a substantial portfolio of 13 marketed and clinical-stage products and has partnered with a number of pharmaceutical companies including Baxter, Merck KGaA, Celltech (part of UCB) and Otsuka.

Innovata plc was formed in July 2005 when ML Laboratories PLC acquired Quadrant Technologies Limited. The company has over 90 employees of whom 65 are engaged in research and development, mainly based at Innovata’s headquarters in Ruddington, Nottingham, United Kingdom. The Company is listed on the London Stock Exchange under the symbol IOV.

About MicroDose Technologies

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries. The MicroDose DPI is a handheld, low cost, breath activated
device which utilizes piezo electronics to efficiently deliver a broad range of compounds independent of inhalation effort. MicroDose is co-developing, with the University of Pittsburgh, an inhaler for the systemic delivery of a nerve agent antidote from the U.S.

Department of Defense, and has several collaborations ongoing with undisclosed major pharmaceutical partners in the respiratory market segment. In addition, MicroDose has internal development programs underway for combination oral dosage products in the areas of diabetes, hypertension and hyperlipidemia.

For further information please visit www.microdose-tech.com

Collaborating with MicroDose s strong technology platform in dry powder inhalation will significantly enhance 3M Drug Delivery Systems capability to provide partner pharmaceutical and biotechnology companies with innovative drug delivery solutions. We are excited to add to the unique breadth and depth of technology that 3M is able to deliver to our customers, said John Sampson, division vice president, 3M Drug Delivery Systems. He added, As we considered potential partners offering next generation technologies, MicroDose clearly stood out with a proven, customer-focused approach that enables flexibility to meet customer requirements with inhalation technology that is truly revolutionary.

The MicroDose Dry Powder Inhaler (DPI) is among a number of key proprietary technology platforms developed by MicroDose. The MicroDose DPI is a handheld, low-cost, breath-activated device that utilizes piezo electronics to efficiently deliver a broad range of compounds. Such compounds include small or large molecule therapeutics for both local and systemic applications. The device promises to be the first completely electronic DPI on the market and represents the next generation in inhaler technology both in performance and ease of use for patients.

Commenting on the transaction, Anand Gumaste, president and chief executive officer, MicroDose, said, “Through this collaboration, MicroDose is able to offer the pharmaceutical and biotechnology industries a fully integrated inhalation product development and manufacturing capability. We are pleased to be partnering with 3M to make this happen.”

Scott Fleming, senior vice president of marketing, MicroDose, added that By combining our innovative inhaler technology platform with 3M s proven leadership in healthcare products and strong brand, we will create a dynamic partnership providing unique inhalation product solutions for an expanded market.

MicroDose and 3M currently are seeking business alliances with pharmaceutical and biotechnology companies interested in the pulmonary delivery of their molecules.

About MicroDose Technologies, Inc.

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privatelyheld drug delivery company, developing advanced pulmonary, combination solid oral dosage, and other technologies for the pharmaceutical and biotechnology industries. The MicroDose DPI has been licensed to Bristol-Myers Squibb for the delivery of inhaled insulin and is currently in development. MicroDose is also co-developing, with the University of Pittsburgh, an inhaled delivery system for a nerve agent antidote for the U.S. Department of Defense. In addition, MicroDose has several collaborations ongoing with undisclosed major pharmaceutical partners in the respiratory market segment.

About 3M Drug Delivery Systems — Part of the 3M Health Care Family 3M Health Care, the largest of seven major 3M businesses, is dedicated to improving the practice, delivery and outcome of care in medical, dental, pharmaceutical, health information and personal care markets. 3M Drug Delivery Systems Division, part of the 3M Health Care family, is a global leader in the development of inhalation and transdermal technologies. As the creator of the first metered dose inhaler, the division history spans more than 50 years of medical innovation as a true pioneer of these technologies in both components as well as total drug delivery systems. Additional information is available at
www.3M.com/dds.

About 3M — A Global, Diversified Technology Company

Every day, 3M people find new ways to make amazing things happen. Wherever they are, whatever they do, the company’s customers know they can rely on 3M to help make their lives better. 3M’s brands include icons such as Scotch, Post-it, Scotchgard, Thinsulate, Scotch-Brite, Nexcare, Filtrete, Command and Dyneon. Serving customers in more than 200 countries around the world, the company’s 67,000 people use their expertise, technologies and global strength to lead in major markets including consumer and office; display and graphics; electronics and  telecommunications; safety, security and protection services; health care; industrial and transportation. For more information, including the latest product and technology news, visit www.3M.com.

This rapid acting insulin product has been developed by QDose, a joint venture company established between Elan and MicroDose, and will be targeted at the treatment of both Type I and II diabetes as a patient-friendly and convenient approach to replacing the subcutaneous insulin injections required to control mealrelated glucose levels.

The UK-based study was conducted in 18 healthy male volunteers and was designed to demonstrate the efficiency of delivery of Elan s dry powder insulin from the MicroDose device. Blood levels of insulin and glucose were measured over time following inhalation of either pure insulin or an insulin-trehalose formulation (a formulation designed to allow long term storage at room temperature). Pulmonary delivery was compared with subcutaneous injected insulin, as a control.

Absorption of the inhaled insulin was rapid with a T max (time to maximum blood concentration) of 37-39 minutes (depending on the formulation) compared with a T max of 102 minutes for the subcutaneous insulin control, providing the opportunity for more rapid and complete control of blood glucose levels at meal times compared with conventional insulin injections. The bio-availability over the initial 3 hours of the inhaled insulin relative to the subcutaneous dose was 23-25% depending on the formulation. These data compare extremely favourably with those of competitor approaches in pulmonary drug delivery.

The MicroDose DPI is an active, multi-unit dose device, which achieves high efficiency powder dispersion independent of patient inhalation effort and has demonstrated excellent dose reproducibility. It is designed to be a lightweight, low cost, pocket-sized device.

These Phase I results are extremely encouraging said Anand Gumaste, CEO of MicroDose. Clearly we are in a highly competitive field, but the outcome of the study positions us strongly as we seek a development partner and move this product through development. For MicroDose, this is the first time that this inhaler device has been tested in clinical trials. The results of this pioneering study are very exciting and prove our ability to develop technologies which deliver active molecules to the required sites of action quickly and effectively. The performance levels we have observed demonstrate clear potential to evaluate other bioactive molecules using this device, commented Scott Fleming, Vice President, Marketing, MicroDose.

Highlights

• The joint venture will be a UK based limited company owned 50% each by Quadrant and MicroDose and will be called QDose.
• The joint venture will initially focus on the development of a pulmonary format of fast acting insulin combining Quadrant’s formulation and particle engineering technologies with MicroDose’s novel dry powder inhaler and filling capabilities.The joint venture aims to find a multinational pharmaceutical partner for the project once clinical trials are underway.
• As part of the financial arrangements Quadrant has invested a total of US$2 million in MicroDose in the form of common stock and a promissory note. Quadrant hasretained the right to expand the activities of the joint venture at any time up to 31. December 2001 to cover the pulmonary delivery of all peptides and proteins.

MicroDose has developed the patented MicroDose dry powder inhaler (DPI) and MicroDose electrostatic deposition system (MEDS). The MicroDose DPI is a hand-held, low cost, breath activated device, which makes novel use of piezo electronics to efficiently deliver a broad range of compounds. This device is the first totally electronic DPI, and represents the next generation in inhaler technology both in performance and ease of use.

Quadrant CEO Iain Ross said the company screened more than 40 different device technologies and evaluated four before selecting MicroDose for the program. Just as important, Quadrant says, MicroDose has developed an electrostatic deposition system for accurate filling of the unit dose blisters for its DPI.

The MicroDose electrostatic deposition system (MEDS) facilitates the accurate and repeatable packaging of microgram to milligram quantities of powdered drugs. This system is currently used to accurately fill the unit dose blisters for the MicroDose DPI. In the oral delivery area, the MEDS system enables combination products, which can bring
new life to drugs soon to go off patent. The MEDS system can also be used in discovery to produce oral dosage forms for dose ranging and clinical studies.

Commenting on today’s announcement, Iain Ross, Chief Executive of Quadrant, said: “Quadrant is committed to building its franchise in the pulmonary delivery of peptides and proteins and we are very pleased to have agreed the formation of this joint venture with MicroDose. We view our relationship with MicroDose as a key strategic partnership in that by combining their pulmonary device and filling capabilities with our formulation and
particle engineering technologies the joint venture will have a compelling offering to present to pharmaceutical partners in respect of the pulmonary delivery of peptides and proteins.”

Anand Gumaste, Chief Executive of MicroDose, added:

“This joint venture allows both MicroDose and Quadrant to fully leverage their technologies in the $20 billion peptides and proteins market. We believe that by combining our technologies, we will be able to offer the market a small, cost effective, patient acceptable system, which can support the delivery of a broad range of peptides and proteins in collaboration with our pharmaceutical partners.”

Quadrant

Listed on the London Stock Exchange in February 1998, Quadrant is a drug delivery company that seeks to apply its novel and proprietary particle formulation technologies to oral, injectable and inhaled medicines, working in partnership with leading pharmaceutical and drug delivery companies.

MicroDose

Located in Monmouth Junction, New Jersey, USA, MicroDose is a privately held drug delivery company specializing in the development of pulmonary, oral and transdermal delivery systems. MicroDose has research and development contracts with six undisclosed pharmaceutical partners.